{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:14:07Z","timestamp":1788902047095,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>A 45-year-old woman with heavily pretreated, recurrent metastatic esthesioneuroblastoma and progressive symptomatic disease underwent first-in-human peptide receptor radionuclide therapy (PRRT) using the somatostatin receptor (SSTR) antagonist DOTA-LM3 labeled with actinium-225 and lutetium-177 (TANDEM). Two PRRT cycles were administered without acute adverse events. Post-cycle-1 SPET\/CT demonstrated intense uptake in local, lymph nodal, osseous, cerebral, mediastinal, and hilar lesions. After cycle-2, molecular imaging documented partial remission, with reduced radiopharmaceutical uptake (partial response according to THERCIST) in most lesions, accompanied by significant clinical improvement with pain reduction. This case demonstrates the feasibility of combined alpha- and beta-emitting SSTR-antagonist PRRT in advanced esthesioneuroblastoma.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006623","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:15:04Z","timestamp":1785766504000},"page":"e964-e967","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Metastatic Esthesioneuroblastoma"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8404-8206","authenticated-orcid":false,"given":"Elisabetta","family":"Perrone","sequence":"first","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"},{"name":"Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Ghai","sequence":"additional","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Eismant","sequence":"additional","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Greifenstein","sequence":"additional","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Paul","family":"Baum","sequence":"additional","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.bulcan.2020.06.002","article-title":"Esthesioneuroblastoma in children, adolescents and young adults","volume":"107","author":"Dumont","year":"2020","journal-title":"Bull Cancer"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.wneu.2019.03.014","article-title":"Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options","volume":"126","author":"Fiani","year":"2019","journal-title":"World Neurosurg"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1002\/hed.26695","article-title":"The value of 68Gallium-DOTATATE PET\/CT in sinonasal neuroendocrine tumor management: a case series","volume":"43","author":"Liu","year":"2021","journal-title":"Head Neck"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/RMR.0000000000000289","article-title":"Doing great with DOTATATE: update on GA-68 DOTATATE positron emission tomography\/computed tomography and magnetic resonance imaging for evaluation of sinonasal tumors","volume":"30","author":"Zlochower","year":"2021","journal-title":"Top Magn Reson Imaging"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/ijnm.ijnm_207_20","article-title":"Ga-68 DOTATATE positron emission tomography\/computed tomography in a rare case of esthesioneuroblastoma","volume":"36","author":"Verma","year":"2021","journal-title":"Indian J Nucl Med"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"CASE2058","DOI":"10.3171\/CASE2058","article-title":"68Ga-DOTATATE PET\/CT and PET\/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases","volume":"1","author":"Roytman","year":"2021","journal-title":"J Neurosurg Case Lessons"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1097\/RLU.0000000000003133","article-title":"68Ga-DOTATATE and 18F-FDG PET\/CT for the management of esthesioneuroblastoma of the sphenoclival region","volume":"45","author":"Dadgar","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/alr.70001","article-title":"Enhancing diagnostic accuracy in sinonasal neuroendocrine tumors: the case for DOTATATE PET over FDG PET","volume":"15","author":"Sabbaj","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RLU.0000000000000705","article-title":"Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3892\/etm.2016.3732","article-title":"Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: a case report","volume":"12","author":"Sabongi","year":"2016","journal-title":"Exp Ther Med"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ons\/opy028","article-title":"Neuroradiological and neuropathological changes after 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of refractory esthesioneuroblastoma","volume":"15","author":"Schneider","year":"2018","journal-title":"Oper Neurosurg"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.119.237990","article-title":"Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma","volume":"61","author":"Hasan","year":"2020","journal-title":"J Nucl Med"},{"key":"R13-20260908","first-page":"5563379","article-title":"Lutetium-177 DOTATATE for the treatment of esthesioneuroblastoma: a case report","volume":"2025","author":"Avila-Rodriguez","year":"2025","journal-title":"Case Rep Oncol Med"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/RLU.0000000000005717","article-title":"Somatostatin receptor-directed theranostics in esthesioneuroblastoma","volume":"50","author":"Zhi","year":"2025","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:01:10Z","timestamp":1788901270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006623"}},"subtitle":["First-in-human \u03b1\/\u03b2 PRRT With Actinium-225\/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT"],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006623","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2026-04-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}